Loading…
Maravai LifeSciences Holdings, Inc. is projected to rise to $8.19 by 2027, a +21% move from its current price of $6.75. MRVI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $6.58 | $6.75 | $6.93 | +0.05% |
| Aug 2 | $6.51 | $6.76 | $7.01 | +0.09% |
| Aug 3 | $6.46 | $6.76 | $7.07 | +0.14% |
| Aug 4 | $6.42 | $6.76 | $7.12 | +0.18% |
| Aug 5 | $6.39 | $6.77 | $7.17 | +0.23% |
| Aug 6 | $6.35 | $6.77 | $7.21 | +0.28% |
| Aug 7 | $6.32 | $6.77 | $7.25 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.32 | $6.77 | $7.25 | +0.32% |
| Week 2 | $6.17 | $6.79 | $7.48 | +0.64% |
| Week 3 | $6.05 | $6.82 | $7.67 | +0.97% |
| Week 4 | $5.96 | $6.84 | $7.84 | +1.29% |
| Week 5 | $5.89 | $6.86 | $7.99 | +1.62% |
| Week 6 | $5.82 | $6.88 | $8.14 | +1.95% |
| Week 7 | $5.76 | $6.90 | $8.27 | +2.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Maravai LifeSciences Holdings, Inc. is a life sciences company that provides products that enable the development of drug therapies, vaccines, cell and gene therapies, and diagnostics across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
It operates through two segments, TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.
The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products.
It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Maravai LifeSciences Holdings, Inc. (MRVI) trades as a life sciences company with a focus on enabling biopharmaceutical development through TRILINK and CYGNUS offerings. The firm is positioned in the healthcare category and carries a current price of $7.04, with a market cap of $2.6B and a rank of 1872.
A major floor 58.1% below — a decisive break under it would weaken the trend.
The nearest floor, 23.0% below — buyers have tended to step in here.
The nearest ceiling, 7.3% above — a clean break opens room to run.
A major ceiling 25.0% above — clearing it would confirm fresh momentum.
Key MRVI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRVI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.73 | Buy | $6.76 | Sell |
| MA 10 | $6.91 | Sell | $6.77 | Sell |
| MA 20 | $6.59 | Buy | $6.57 | Buy |
| MA 50 | $5.71 | Buy | $5.83 | Buy |
| MA 100 | $4.59 | Buy | $5.05 | Buy |
| MA 200 | $4.01 | Buy | $4.39 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.80 | Neutral |
| Stoch RSI (14) | 12.63 | Buy |
| CCI (20) | 25.47 | Neutral |
| Williams %R (14) | -55.68 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | 3.69 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 44.32 | Neutral |
| TRIX (15) | 1.02 | Buy |
| Awesome (5,34) | 0.56 | Buy |
| Ultimate (7,14,28) | 46.19 | Neutral |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 6.63 | Buy |
| ADX (14) | 36.60 | Buy |
| ATR (14) | 0.16 | Info |
The 30-day technical picture shows a bullish tilt, with RSI14 at 80 indicating strong momentum near the upper end of its range. The stock is trading above both the SMA50 ($5.11) and the SMA200 ($3.80), suggesting an uptrend may persist in the near term.
The immediate price action sits at a resistance level of $7.04, with a support level at $4.83. The 30-day range spans from $5.79 to $8.56, highlighting notable volatility. The stock carries an annualized volatility of 60%, underscoring potential outsized moves in either direction in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.83 | $6.75 | $9.40 | 0% | Neutral | |
| $6.57 | $8.19 | $10.79 | +21% | Bullish | |
| $8.33 | $10.68 | $14.58 | +58% | Bullish | |
| $10.40 | $13.62 | $19.12 | +102% | Bullish | |
| $12.47 | $16.65 | $23.93 | +147% | Bullish | |
| $14.63 | $19.89 | $29.17 | +195% | Bullish | |
| $15.33 | $21.18 | $31.64 | +214% | Bullish | |
| $16.88 | $23.68 | $35.96 | +251% | Bullish | |
| $18.83 | $26.79 | $41.32 | +297% | Bullish | |
| $20.99 | $30.29 | $47.38 | +349% | Bullish | |
| $32.35 | $49.69 | $82.50 | +636% | Bullish | |
| $73.85 | $126.20 | $228.55 | +17.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.83 | $6.75 | $7.88 | +0.00% |
| August 2026 | $5.99 | $7.02 | $8.41 | +3.97% |
| September 2026 | $5.96 | $7.04 | $8.55 | +0.29% |
| October 2026 | $6.06 | $7.21 | $8.84 | +2.42% |
| November 2026 | $6.29 | $7.52 | $9.30 | +4.29% |
| December 2026 | $6.29 | $7.55 | $9.40 | +0.44% |
Click any year to see its month-by-month MRVI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MRVI is projected to trade between $2.83 and $9.40, averaging $6.75 — a potential gain of 0% from today's $6.75. A consolidation phase looks the most probable path here.
Maravai LifeSciences Holdings, Inc.'s 2027 outlook centres on $8.19, within a $6.57 to $10.79 range. That is up +21% on the projected 2026 average. That marks a +21% change versus current levels. Momentum favours further upside here.
By 2028, MRVI could reach as high as $14.58, with a base case around $10.68 and support toward $8.33 — roughly +58% from $6.75. Buyers look set to stay in control over this stretch.
Expect MRVI to range from $10.40 to $19.12 through 2029. The $13.62 average target implies a +102% move from current prices. That is up +28% on the projected 2028 average. Momentum favours further upside here.
The MRVI price prediction for 2030 points to an average of $16.65 (low $12.47, high $23.93) — a potential gain of +147% on today's $6.75. Buyers look set to stay in control over this stretch.
In 2031, MRVI is projected to trade between $14.63 and $29.17, averaging $19.89 — a potential gain of +195% from today's $6.75. That is up +19% on the projected 2030 average. Momentum favours further upside here.
Maravai LifeSciences Holdings, Inc.'s 2032 outlook centres on $21.18, within a $15.33 to $31.64 range. That is up +7% on the projected 2031 average. That marks a +214% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MRVI could reach as high as $35.96, with a base case around $23.68 and support toward $16.88 — roughly +251% from $6.75. Momentum favours further upside here.
Expect MRVI to range from $18.83 to $41.32 through 2034. The $26.79 average target implies a +297% move from current prices. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MRVI price prediction for 2035 points to an average of $30.29 (low $20.99, high $47.38) — a potential gain of +349% on today's $6.75. Momentum favours further upside here.
In 2040, MRVI is projected to trade between $32.35 and $82.50, averaging $49.69 — a potential gain of +636% from today's $6.75. That is up +64% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Maravai LifeSciences Holdings, Inc.'s 2050 outlook centres on $126.20, within a $73.85 to $228.55 range. That is up +154% on the projected 2040 average. That marks a +17.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in MRVI today (≈ 148.148148 MRVI) could be worth
$18,696.14
+$17,696.14 (+1770%) by 2050 · US Dollar
Based on the average projected MRVI price of $126.2 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRVIwould be worth at today's price.
$1,000 invested in MRVI on Jul 30, 2025 (≈ 414.937745 MRVI) would be worth
$2,800.83
+$1,800.83 (+180.1%) today · 2.80× · US Dollar
Based on a MRVI entry price of $2.41 vs. today's $6.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.05 | $957.45 | -4.3% |
| 1 month ago | $6.24 | $1,081.73 | +8.2% |
| 3 months ago | $3.73 | $1,809.65 | +81.0% |
| 6 months ago | $3.36 | $2,008.93 | +100.9% |
| 1 year ago | $2.41 | $2,800.83 | +180.1% |
| All time (5.0y) ago | $44.32 | $152.3 | -84.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRVI forecast.
Our base-case forecast reaches $14.00 around 2030.
Implied market cap at $14.00: $2.07B
The multi-year forecast depicts a clearly bullish trajectory after 2026, with average prices rising to new highs across the horizon. In 2030 the forecasted average price is $16.93, with a min of $12.36 and a max of $25.04, and a projected ROI of 140.4%. By 2040, the average price is $48.10 (min $29.75, max $83.45) with a 583.3% ROI, and by 2050 the average price is $119.65 (min $64.96, max $228.24) with a 1599.5% ROI.
The forecast also marks bullish sentiment in later years, reflecting expected sustained upside potential across the long horizon.
These figures indicate significant upside potential if the forecast plays out, but they are estimates and not guarantees. Market conditions, regulatory developments, and other unforeseen factors can influence actual prices and returns over time.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $16.93, with a min of $12.36 and a max of $25.04; the associated ROI is 140.4%.
Forecasts show rising prices with substantial long-term upside (2030–2050). The 2030 average is $16.93 and 2050 average is $119.65, with a max of $228.24, and ROI up to 1599.5%. However, near-term evidence for 2026 is neutral, and outcomes are not guaranteed.
Yes. The forecast for 2050 shows an average price of $119.65 and a maximum of $228.24, indicating the possibility of reaching or exceeding $100 within the forecast horizon.
MRVI's current price is $7.04. RSI14 is 80, indicating strong momentum. The stock trades above the SMA50 ($5.11) and the SMA200 ($3.80), with a 30-day range from $5.79 to $8.56 and a support at $4.83 and resistance at $7.04.
For 2040, the forecasted average price is $48.10 (min $29.75, max $83.45) with a 583.3% ROI. For 2050, the forecasted average price is $119.65 (min $64.96, max $228.24) with a 1599.5% ROI.
Maravai LifeSciences Holdings, Inc. Community Discussion
0Share your Maravai LifeSciences Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.